ANTONIO JOSÉ TORRES GARCÍA-rekin lankidetzan egindako argitalpenak (12)

2022

  1. The impact of surgical delay on resectability of colorectal cancer: An international prospective cohort study

    Colorectal Disease, Vol. 24, Núm. 6, pp. 708-726

2021

  1. Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic

    British Journal of Surgery, Vol. 108, Núm. 12, pp. 1448-1464

  2. Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection

    BJS Open

  3. Impact of COVID-19 on vascular patients worldwide: Analysis of the COVIDSurg data

    Journal of Cardiovascular Surgery, Vol. 62, Núm. 6, pp. 558-570

  4. Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic

    Colorectal Disease, Vol. 23, Núm. 3, pp. 732-749

  5. Trocar-site incisional hernia after laparoscopic colorectal surgery: a significant problem? Incidence and risk factors from a single-center cohort

    Surgical Endoscopy, Vol. 35, Núm. 6, pp. 2907-2913

2020

  1. Extraction-site incisional hernia after laparoscopic colorectal surgery: should we carry out a study about prophylactic mesh closure?

    Surgical Endoscopy, Vol. 34, Núm. 9, pp. 4048-4052

1997

  1. Prognostic value of flow cytometric DNA analysis in non-small-cell lung cancer: Rationale of sequential processing of frozen and paraffin-embedded tissue

    World Journal of Surgery, Vol. 21, Núm. 3, pp. 323-329

1995

  1. Serum CEA, CA125, and SCC antigens and tumor recurrence in resectable non-small cell lung cancer

    International Journal of Biological Markers, Vol. 10, Núm. 1, pp. 5-10

1994

  1. Epidermal growth factor receptor in non-small cell cancer of the lung

    Archivos de bronconeumología, Vol. 30, Núm. 6, pp. 282-286

  2. Quantitative analysis of carcinoembryonic antigen, squamous cell carcinoma antigen, CA 125, and CA 50 cytosolic content in non‐small cell lung cancer

    Cancer, Vol. 73, Núm. 9, pp. 2305-2311

1993

  1. UTILIDAD DEL ANTIGENO CA 125 EN SUERO COMO FACTOR PRONOSTICO DE SUPERVIVENCIA EN PACIENTES CON CARCINOMA PULMONAR NO MICROCITICO

    Neoplasia, Vol. 10, Núm. 6, pp. 192-196